CN115698005A - 稠环类AhR抑制剂 - Google Patents

稠环类AhR抑制剂 Download PDF

Info

Publication number
CN115698005A
CN115698005A CN202180036756.XA CN202180036756A CN115698005A CN 115698005 A CN115698005 A CN 115698005A CN 202180036756 A CN202180036756 A CN 202180036756A CN 115698005 A CN115698005 A CN 115698005A
Authority
CN
China
Prior art keywords
alkyl
alkoxy
amino
group
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180036756.XA
Other languages
English (en)
Other versions
CN115698005B (zh
Inventor
刘斌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Xuanzhu Pharma Co Ltd
Original Assignee
Xuanzhu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xuanzhu Pharma Co Ltd filed Critical Xuanzhu Pharma Co Ltd
Publication of CN115698005A publication Critical patent/CN115698005A/zh
Application granted granted Critical
Publication of CN115698005B publication Critical patent/CN115698005B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明属于医药技术领域，具体涉及一类稠环类AhR抑制剂化合物、其药学上可接受的盐、其酯或其立体异构体，含有所述化合物、其药学上可接受的盐、其酯或其立体异构体的药物组合物及制剂，制备所述化合物、其药学上可接受的盐、其酯或其立体异构体的方法，以及所述化合物、其药学上可接受的盐、其酯或其立体异构体的用途。

Description

PCT国内申请，说明书已公开。

Claims (13)

  1. PCT国内申请，权利要求书已公开。
CN202180036756.XA 2020-12-18 2021-12-14 稠环类AhR抑制剂 Active CN115698005B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202011505736 2020-12-18
CN2020115057366 2020-12-18
PCT/CN2021/137679 WO2022127753A1 (zh) 2020-12-18 2021-12-14 稠环类AhR抑制剂

Publications (2)

Publication Number Publication Date
CN115698005A true CN115698005A (zh) 2023-02-03
CN115698005B CN115698005B (zh) 2024-02-06

Family

ID=82060055

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180036756.XA Active CN115698005B (zh) 2020-12-18 2021-12-14 稠环类AhR抑制剂

Country Status (2)

Country Link
CN (1) CN115698005B (zh)
WO (1) WO2022127753A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117229284A (zh) * 2023-11-10 2023-12-15 上海泽德曼医药科技有限公司 三环稠杂环类化合物、其制备方法及其在医药上的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102089308A (zh) * 2008-07-07 2011-06-08 艾科睿控股公司 Pi3k亚型选择性抑制剂
CN102753548A (zh) * 2009-12-23 2012-10-24 武田药品工业株式会社 作为syk抑制剂的稠合的杂芳族吡咯烷酮
CN107108609A (zh) * 2014-12-18 2017-08-29 武田药品工业株式会社 稠合杂芳族吡咯烷酮的固态形式
CN108239083A (zh) * 2016-12-26 2018-07-03 上海正基医药科技有限公司 芳香烃受体调节剂

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210379033A1 (en) * 2018-10-17 2021-12-09 Magenta Therapeutics Inc. Methods of treating cancer with aryl hydrocarbon receptor antagonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102089308A (zh) * 2008-07-07 2011-06-08 艾科睿控股公司 Pi3k亚型选择性抑制剂
CN102753548A (zh) * 2009-12-23 2012-10-24 武田药品工业株式会社 作为syk抑制剂的稠合的杂芳族吡咯烷酮
CN107108609A (zh) * 2014-12-18 2017-08-29 武田药品工业株式会社 稠合杂芳族吡咯烷酮的固态形式
CN108239083A (zh) * 2016-12-26 2018-07-03 上海正基医药科技有限公司 芳香烃受体调节剂

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117229284A (zh) * 2023-11-10 2023-12-15 上海泽德曼医药科技有限公司 三环稠杂环类化合物、其制备方法及其在医药上的应用
CN117229284B (zh) * 2023-11-10 2024-02-06 上海泽德曼医药科技有限公司 三环稠杂环类化合物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
CN115698005B (zh) 2024-02-06
WO2022127753A1 (zh) 2022-06-23

Similar Documents

Publication Publication Date Title
CN109983007B (zh) 酰胺类衍生物抑制剂及其制备方法和应用
CN109311864B (zh) 杂芳基取代的吡啶及使用方法
WO2020239077A1 (zh) 含氮杂环类衍生物调节剂、其制备方法和应用
RU2537945C2 (ru) Триазиновые, пиримидиновые и пиридиновые аналоги и их применение в качестве терапевтических агентов и диагностических проб
JP5735987B2 (ja) 窒素含有へテロアリール誘導体
CN115151532A (zh) 喹喔啉二酮衍生物作为kras g12c突变蛋白的不可逆抑制剂
TW202043241A (zh) 作為mcl-1抑制劑的大環稠合的吡唑
CN112236429A (zh) 用作ii型irak抑制剂的杂芳基化合物及其用途
CN115279749A (zh) Shp2抑制剂及其组合物和应用
CN113490670B (zh) 含氮多环稠环类化合物,其药物组合物、制备方法和用途
CN110520416B (zh) 多取代吡啶酮类衍生物、其制备方法及其医药用途
CN114181208B (zh) 三并环类AhR抑制剂及其用途
CN114644627B (zh) AhR抑制剂及其用途
CN113387962A (zh) 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
CN114667289A (zh) 杂芳基血浆激肽释放酶抑制剂
EP3998270A1 (en) Alkyne derivative, preparation method for same, and uses thereof
WO2021244609A1 (zh) 具有大环结构的化合物及其用途
CN111592541B (zh) 大环类激酶抑制剂及其用途
CN115698005B (zh) 稠环类AhR抑制剂
CN111971278A (zh) 用作irak抑制剂的喹啉化合物及其用途
CN114437116A (zh) 杂环化合物及其制备方法、药物组合物和应用
CN114181212B (zh) 哒嗪酮类AhR抑制剂
CN114369097B (zh) 杂芳环类AhR抑制剂
CN112409361B (zh) Tam抑制剂及其用途
CN115636828A (zh) 三并环类AhR抑制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant